Korro Reports Second Quarter 2025 Financial Results and Provides Business Updates

Core Insights - Korro Bio, Inc. is progressing well in its Phase 1/2a REWRITE clinical trial for KRRO-110, with an interim readout expected in the second half of 2025, indicating potential best-in-class status for the treatment of Alpha-1 Antitrypsin Deficiency (AATD) [1][2][4] - The European Medicines Agency (EMA) has granted Orphan Drug Designation to KRRO-110, which provides various development incentives [1][5] - The company ended Q2 2025 with $119.6 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into 2027 [6][19] Clinical Development Updates - Over 80% of planned healthy volunteers have been dosed in the REWRITE trial, with no serious adverse events or dose-limiting toxicities reported [1][5] - The REWRITE trial consists of two parts: Part 1 (single ascending doses) and Part 2 (multiple ascending doses), with completion of the trial anticipated in 2026 [4][10] - The interim data from Part 1 is expected to provide insights into the pharmacologically relevant dose levels for PiZZ patients [5][10] Financial Performance - Collaboration revenue for Q2 2025 was $1.5 million, a significant increase from no collaboration revenue in Q2 2024, attributed to the partnership with Novo Nordisk [7] - Research and Development (R&D) expenses rose to $21.0 million in Q2 2025 from $17.1 million in Q2 2024, driven by increased personnel and research costs [8] - General and Administrative (G&A) expenses increased to $7.6 million in Q2 2025 from $7.0 million in Q2 2024, primarily due to higher personnel-related expenses [9] Strategic Initiatives - The company is executing its 3-2-1 strategy, aiming to establish three clinical-stage development programs targeting two tissue types by leveraging its OPERA® platform [2][5] - A development candidate for a rare metabolic disorder program is expected to be announced by the end of 2025, which will be administered subcutaneously [1][13] - Korro continues to advance its collaboration with Novo Nordisk, focusing on cardiometabolic diseases with high unmet clinical needs [5][13]